Evaluation of the Current Disease Scoring Systems in Familial Mediterranean Fever

Rare Diseases of the Immune System

Volumn 3, Issue , 2015, Pages 107-118

  Demirkaya, Erkan ^a   Livneh, Avi ^b,c,d  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b SHEBA MEDICAL CENTER   (Israel)

^c HELLER INSTITUTE OF MEDICAL RESEARCH   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Aphthous Stomatitis; Autoinflammatory Disease; Colchicine Treatment; Familial Mediterranean Fever; Nominal Group Technique

Indexed keywords

EID: 84970006460     PISSN: 22826505     EISSN: 22836403     Source Type: Book Series    
DOI: 10.1007/978-3-319-14615-7_7     Document Type: Chapter

References (30)

1. Thomson W. Electrical units of measurement. Pop Lect Addresses. 1883;1(1):80–143.
2. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28(3):551–8.
3. Piram M, Frenkel J, Gattorno M, Ozen S, Lachmann HJ, Goldbach-Mansky R, Hentgen V, Neven B, Stojanovic KS, Simon A, Kuemmerle-Deschner J, Hoffman H, Stojanov S, Duquesne A, Pillet P, Martini A, Pouchot J, Kone-Paut I, EUROFEVER and EUROTRAPS Networks. A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) consensus conference. Ann Rheum Dis. 2011;70(2):309–14.
4. Piram M, Kone-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, Stojanov S, Simon A, Finetti M, Sormani MP, Martini A, Gattorno M, Ruperto N. Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2013. doi:10.1136/annrheumdis-2013-203666.
5. Buskila D, Zaks N, Neumann L, Livneh A, Greenberg S, Pras M, Langevitz P. Quality of life of patients with familial Mediterranean fever. Clin Exp Rheumatol. 1997;15(4):355–60.
6. La Regina M, Ben-Chetrit E, Gasparyan AY, Livneh A, Ozdogan H, Manna R. Current trends in colchicine treatment in familial Mediterranean fever. Clin Exp Rheumatol. 2013;31(3 Suppl 77):41–6.
7. Berkun Y, Ben-Chetrit E, Klar A, Ben-Chetrit E. Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever–are they more frequent? Semin Arthritis Rheum. 2007;36(5):316–21. doi:10.1016/j.semarthrit.2006.11.002.
8. Ozen S, Aktay N, Lainka E, Duzova A, Bakkaloglu A, Kallinich T. Disease severity in children and adolescents with familial Mediterranean fever: a comparative study to explore environmental effects on a monogenic disease. Ann Rheum Dis. 2009;68(2):246–8. doi: 10.1136/ard.2008.092031.
9. Fidanci BE, Demirkaya E, Acikel C, Fidanci K, Karaman D, Yildiz D, Konukbay D, Polat A, Basbozkurt G, Topaloglu R, Cimaz R, Ravelli A, Ozen S. The invisible part of the iceberg: qualitative aspects of childhood vasculitis. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S122–7.
10. Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi B, Magni-Manzoni S, Ruperto N, Pistorio A, Pederzoli S, Civino A, Guseinova D, Masala E, Viola S, Martini A, Ravelli A. A new approach to clinical care of juvenile idiopathic arthritis: the juvenile arthritis multidimensional assessment report. J Rheumatol. 2011;38(5):938–53. doi:10.3899/jrheum.100930.
11. Konukbay D, Yildiz D, Acikel C, Karaman D, Fidanci BE, Bilginer Y, Polat A, Kone-Paut I, Frenkel J, Gattorno M, Ravelli A, Ozen S, Demirkaya E. Evaluation of biopsychosocial aspects of patients with juvenile autoinflammatory disease: a qualitative study. Ann Paediatr Rheum. 2014;3(2):62–71.
12. Konukbay D, Yildiz D, Acikel C, Sozeri B, Makay B, Ayaz NA, Barut K, Kısaarslan A, Bilginer Y, Peru H, Erdogan O, Unsal E, Kasapcopur O, Gunduz Z, Ozen S, Demirkaya E. Development and validation of juvenile autoinflammatory disease multidimensional assessment report (JAIMAR). Pediatr Rheumatol. 2014;12 Suppl 1:O23.
13. Ozturk MA, Kanbay M, Kasapoglu B, Onat AM, Guz G, Furst DE, Ben-Chetrit E. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S77–86.
14. Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, Kasapcopur O, Kasifoglu T, Kisacik B, Ozdogan H, Tunca M, Acikel C. FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis. 2014;73(5):897–901.
15. Lidar M, Kedem R, Langevitz P, Pras M, Livneh A. Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. J Rheumatol. 2003;30(12):2620–3.
16. Tweezer-Zaks N, Rabinovich E, Lidar M, Livneh A. Interferon-alpha as a treatment modality for colchicine-resistant familial Mediterranean fever. J Rheumatol. 2008;35(7):1362–5.
17. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm. 2007;64(5):4–7.
18. DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–9.
19. Faught E. Adherence to antiepilepsy drug therapy. Epilepsy Behav. 2012;25:297–302.
20. Moore S. Facilitating oral chemotherapy treatment and compliance through patient/family-focused education. Cancer Nurs. 2007;30(2):112–21.
21. Chambers SA, Rahman A, Isenberg DA. Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology (Oxford, England). 2007;46(6):895–8.
22. Osterberg L, Blaschke T. Drug therapy adherence to medication. N Engl J Med. 2005;353:487–97.
23. Rigante D, La Torraca I, Avallone L, Pugliese AL, Gaspari S, Stabile A. The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever. Eur Rev Med Pharmacol Sci. 2006;10(4):173–8.
24. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351(9103):659–64.
25. Yesilkaya S, Acıkel C, Eren Fidanci B, Sozeri B, Aktay Ayaz N, Akıncı N, Ozcelik G, Kavukcu S, Aydogan U, Ozenc S, Emre S, Donmez O, Yuksel S, Delibas A, Berdelli A, Poyrazoglu H, Saldir M, Cakar N, Peru H, Bakkaloglu S, Tabel Y, Sari O, Polat A, Basbozkurt G, Unsal E, Gok F, Kasapcopur O, Ozen S, Demirkaya E, FMF Arthritis Vasculitis and Orphan disease Research in Paediatric Rheumatology (FAVOR). Developing of a new scale for assessing the adherence to colchicines treatment in pediatric patients with FMF. Pediatr Rheumatol. 2013;11 Suppl 2:P194.
26. Fidanci BE, Yesilkaya S, Acikel C, Ozden A, Simsek D, Yildiz F, Kisacik B, Sayarlıoglu M, Akar S. Validity and reliability of medication adherence scale in FMF (adult version). Pediatr Rheumatol. 2014;12 Suppl 1:P243.
27. Pras E, Livneh A, Balow Jr JE, Pras E, Kastner DL, Pras M, Langevitz P. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet. 1998;75(2):216–9.
28. Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, Rabinovitz E, Livneh A. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum. 2005;35(1):57–64.
29. Kalkan G, Demirkaya E, Acikel CH, Polat A, Peru H, Karaoglu A, Sari E, Dursun I, Gok F, Ozen S, Vasculitis FMFA, Orphan Disease Research in Paediatric R. Evaluation of the current disease severity scores in paediatric FMF: is it necessary to develop a new one? Rheumatology (Oxford, England). 2012;51(4):743–8.
30. Demirkaya E, Acikel C, Gul A, Gattorno M, Ben-Chetrit E, Ozdogan H, Hashkes P, Polat A, Livneh A, Ozen S. PReS-FINAL-2328 developing and validating the new severity score for FMF. Pediatr Rheumatol. 2013;11 Suppl 2:P318.